Apotex sells US copies of 2 of the blockbuster drugs on this tracker, is approved for 2 more, and has 2 filed or in development. Those brands earned $50.4B in 2025. Of the 70 makers we follow, 7 are lined up to copy more of these drugs.
| Drug | Apotex's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| PomalystGeneric · Bristol Myers Squibb · US LOE 2026 | FDA-approved 11 Jun 2024; launched 2 Mar 2026 | 3 on sale · 6 approvedof 10 other makers listed | $2.7B |
| JanuviaGeneric · Merck · US LOE 2026 | FDA-approved 20 Jan 2026; launched 3 Jun 2026; says it is eligible for 180-day shared exclusivity | 1 on sale · 1 approvedof 2 other makers listed | $2.5B |
| Drug | Apotex's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| OpsumitGeneric · Johnson & Johnson · US LOE 2026 | FDA-approved 9 Jan 2024; first filer; FDA has not decided whether it keeps 180-day shared exclusivity | 2 on sale · 9 approvedof 11 other makers listed | $2.3B |
| OzempicGeneric · Novo Nordisk · US LOE 2032 | Tentatively approved Apr 2026; settled, terms confidential. Launch expected after final approval, following patent expiry in 2032 | 0 on sale · 0 approvedof 6 other makers listed | ≈$19.3B |
| Drug | Apotex's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| XareltoGeneric · Bayer / Johnson & Johnson · US LOE 2025 | FDA-approved 2 Mar 2026, not marketed | 1 on sale · 18 approvedof 19 other makers listed | ≈$5.3B |
| XtandiGeneric · Capsules · Astellas / Pfizer · US LOE 2027 | Capsules: FDA-approved 22 Apr 2022, not marketed | 0 on sale · 2 approvedof 5 other makers listed | ≈$6.0B |
| DescovyGeneric · Gilead · US LOE 2031 | FDA-approved 17 May 2024, not marketed; settled 2022 | 0 on sale · 2 approvedof 5 other makers listed | $2.8B |
| Drug | Apotex's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| JakafiGeneric · Incyte · US LOE 2028 | Filed with the FDA; in litigation | 0 on sale · 0 approvedof 9 other makers listed | $3.1B |
| VyndaqelGeneric · Vyndamax · Pfizer · US LOE 2031 | Vyndamax: filed with the FDA; in litigation | 0 on sale · 0 approvedof 3 other makers listed, plus unnamed filers | $6.4B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Apotex's own sales. See the launch tracker →
Each row is a copy Apotex sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Apotex's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Apotex's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Apotex: IPO pricing, 10 Jun 2026; Apotex: Q1 fiscal 2027 results.